Investigational Agents in HCV: CME/CE-Certified Expert Analysis From Boston

[Guest guest]

CME/CE-Certified Expert Analysis From BostonDate: Sat, 19 Jan 2008 11:00:00

-0500

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CME/CE-Certified Expert AnalysisClick to AccessUpdate on Investigational Agents

in HCV: 2007CCO Independent Conference Coverage of the2007 Annual Meeting of the

American Association for the Study of Liver Diseases*November 2-6, 2007 |

Boston, Massachusetts

Dear colleague,

While attending the liver disease meeting in Boston, I met with Nezam H. Afdhal,

MD, FRCPI, andIra M. son, MD, to discuss the latest data in investigational

agents in HCV treatment. We had an engaging discussion that is now available on

the Clinical Care Options Web site as a CME/CE-certified Expert Analysis.

Topics include:

Clinical Studies of the Investigational Protease Inhibitor Telaprevir

Efficacy, Safety, and Resistance Analysis With R1626

Treatment With R7128 in Previous Nonresponders

Clinical Studies With NS5B Polymerase Inhibitors VCH-759 and GS-9190

Anti-HCV Activity Observed With Nitazoxanide

Albinterferon alfa-2b in Treatment-Naive or Treatment-Experienced Patients

Phase IIa Trial of Controlled-Release Recombinant Interferon alfa-2b

Anti-HCV Activity With GI-5005, a Yeast-Based Immunotherapy

To read about these latest advances presented at the liver disease meeting,

click here.

I encourage you to review this Expert Analysis for data important to your

clinical practice.

Regards,

R. , MDAssociate Professor of MedicineDivision of Gastroenterology,

Hepatology, and NutritionDirector of Hepatology and Liver

TransplantationUniversity of Florida College of MedicineGainesville, Florida

This Expert Analysis is located online

at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007.aspx

Physicians:Jointly sponsored by Postgraduate Institute for Medicine and Clinical

Care Options, LLC.

Nurses:Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:Postgraduate Institute for Medicine is accredited by the

Accreditation Council for Pharmacy Education as a provider of continuing

pharmacy education. Pharmacy credit hours provided through the cosponsorship of

Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Release date: January 7, 2008Expiration date: January 6, 2009

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences,

Roche, Schering-Plough, and Vertex.

| Not a member yet? Click here | RSS | Hepatitis Podcasts | Bookstore

To ensure you receive Clinical Care Options educational materials by

email,please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Need to know the score, the latest news, or you need your Hotmail®-get your

" fix " .

http://www.msnmobilefix.com/Default.aspx

[Guest guest]

CME/CE-Certified Expert Analysis From BostonDate: Sat, 19 Jan 2008 11:00:00

-0500

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CME/CE-Certified Expert AnalysisClick to AccessUpdate on Investigational Agents

in HCV: 2007CCO Independent Conference Coverage of the2007 Annual Meeting of the

American Association for the Study of Liver Diseases*November 2-6, 2007 |

Boston, Massachusetts

Dear colleague,

While attending the liver disease meeting in Boston, I met with Nezam H. Afdhal,

MD, FRCPI, andIra M. son, MD, to discuss the latest data in investigational

agents in HCV treatment. We had an engaging discussion that is now available on

the Clinical Care Options Web site as a CME/CE-certified Expert Analysis.

Topics include:

Clinical Studies of the Investigational Protease Inhibitor Telaprevir

Efficacy, Safety, and Resistance Analysis With R1626

Treatment With R7128 in Previous Nonresponders

Clinical Studies With NS5B Polymerase Inhibitors VCH-759 and GS-9190

Anti-HCV Activity Observed With Nitazoxanide

Albinterferon alfa-2b in Treatment-Naive or Treatment-Experienced Patients

Phase IIa Trial of Controlled-Release Recombinant Interferon alfa-2b

Anti-HCV Activity With GI-5005, a Yeast-Based Immunotherapy

To read about these latest advances presented at the liver disease meeting,

click here.

I encourage you to review this Expert Analysis for data important to your

clinical practice.

Regards,

R. , MDAssociate Professor of MedicineDivision of Gastroenterology,

Hepatology, and NutritionDirector of Hepatology and Liver

TransplantationUniversity of Florida College of MedicineGainesville, Florida

This Expert Analysis is located online

at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007.aspx

Physicians:Jointly sponsored by Postgraduate Institute for Medicine and Clinical

Care Options, LLC.

Nurses:Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:Postgraduate Institute for Medicine is accredited by the

Accreditation Council for Pharmacy Education as a provider of continuing

pharmacy education. Pharmacy credit hours provided through the cosponsorship of

Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Release date: January 7, 2008Expiration date: January 6, 2009

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences,

Roche, Schering-Plough, and Vertex.

| Not a member yet? Click here | RSS | Hepatitis Podcasts | Bookstore

To ensure you receive Clinical Care Options educational materials by

email,please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Need to know the score, the latest news, or you need your Hotmail®-get your

" fix " .

http://www.msnmobilefix.com/Default.aspx

[Guest guest]

CME/CE-Certified Expert Analysis From BostonDate: Sat, 19 Jan 2008 11:00:00

-0500

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CME/CE-Certified Expert AnalysisClick to AccessUpdate on Investigational Agents

in HCV: 2007CCO Independent Conference Coverage of the2007 Annual Meeting of the

American Association for the Study of Liver Diseases*November 2-6, 2007 |

Boston, Massachusetts

Dear colleague,

While attending the liver disease meeting in Boston, I met with Nezam H. Afdhal,

MD, FRCPI, andIra M. son, MD, to discuss the latest data in investigational

agents in HCV treatment. We had an engaging discussion that is now available on

the Clinical Care Options Web site as a CME/CE-certified Expert Analysis.

Topics include:

Clinical Studies of the Investigational Protease Inhibitor Telaprevir

Efficacy, Safety, and Resistance Analysis With R1626

Treatment With R7128 in Previous Nonresponders

Clinical Studies With NS5B Polymerase Inhibitors VCH-759 and GS-9190

Anti-HCV Activity Observed With Nitazoxanide

Albinterferon alfa-2b in Treatment-Naive or Treatment-Experienced Patients

Phase IIa Trial of Controlled-Release Recombinant Interferon alfa-2b

Anti-HCV Activity With GI-5005, a Yeast-Based Immunotherapy

To read about these latest advances presented at the liver disease meeting,

click here.

I encourage you to review this Expert Analysis for data important to your

clinical practice.

Regards,

R. , MDAssociate Professor of MedicineDivision of Gastroenterology,

Hepatology, and NutritionDirector of Hepatology and Liver

TransplantationUniversity of Florida College of MedicineGainesville, Florida

This Expert Analysis is located online

at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007.aspx

Physicians:Jointly sponsored by Postgraduate Institute for Medicine and Clinical

Care Options, LLC.

Nurses:Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:Postgraduate Institute for Medicine is accredited by the

Accreditation Council for Pharmacy Education as a provider of continuing

pharmacy education. Pharmacy credit hours provided through the cosponsorship of

Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Release date: January 7, 2008Expiration date: January 6, 2009

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences,

Roche, Schering-Plough, and Vertex.

| Not a member yet? Click here | RSS | Hepatitis Podcasts | Bookstore

To ensure you receive Clinical Care Options educational materials by

email,please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Need to know the score, the latest news, or you need your Hotmail®-get your

" fix " .

http://www.msnmobilefix.com/Default.aspx

[Guest guest]

CME/CE-Certified Expert Analysis From BostonDate: Sat, 19 Jan 2008 11:00:00

-0500

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CME/CE-Certified Expert AnalysisClick to AccessUpdate on Investigational Agents

in HCV: 2007CCO Independent Conference Coverage of the2007 Annual Meeting of the

American Association for the Study of Liver Diseases*November 2-6, 2007 |

Boston, Massachusetts

Dear colleague,

While attending the liver disease meeting in Boston, I met with Nezam H. Afdhal,

MD, FRCPI, andIra M. son, MD, to discuss the latest data in investigational

agents in HCV treatment. We had an engaging discussion that is now available on

the Clinical Care Options Web site as a CME/CE-certified Expert Analysis.

Topics include:

Clinical Studies of the Investigational Protease Inhibitor Telaprevir

Efficacy, Safety, and Resistance Analysis With R1626

Treatment With R7128 in Previous Nonresponders

Clinical Studies With NS5B Polymerase Inhibitors VCH-759 and GS-9190

Anti-HCV Activity Observed With Nitazoxanide

Albinterferon alfa-2b in Treatment-Naive or Treatment-Experienced Patients

Phase IIa Trial of Controlled-Release Recombinant Interferon alfa-2b

Anti-HCV Activity With GI-5005, a Yeast-Based Immunotherapy

To read about these latest advances presented at the liver disease meeting,

click here.

I encourage you to review this Expert Analysis for data important to your

clinical practice.

Regards,

R. , MDAssociate Professor of MedicineDivision of Gastroenterology,

Hepatology, and NutritionDirector of Hepatology and Liver

TransplantationUniversity of Florida College of MedicineGainesville, Florida

This Expert Analysis is located online

at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007.aspx

Physicians:Jointly sponsored by Postgraduate Institute for Medicine and Clinical

Care Options, LLC.

Nurses:Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:Postgraduate Institute for Medicine is accredited by the

Accreditation Council for Pharmacy Education as a provider of continuing

pharmacy education. Pharmacy credit hours provided through the cosponsorship of

Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Release date: January 7, 2008Expiration date: January 6, 2009

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences,

Roche, Schering-Plough, and Vertex.

| Not a member yet? Click here | RSS | Hepatitis Podcasts | Bookstore

To ensure you receive Clinical Care Options educational materials by

email,please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Need to know the score, the latest news, or you need your Hotmail®-get your

" fix " .

http://www.msnmobilefix.com/Default.aspx